Table 1 Tumor size evolution on breast MRI
From: Medical treatment of mammary desmoid-type fibromatosis: which benefit?
IRM date | Tumoral size (mm) max/min | Tumoral volume (cm3) | Evolutiona (%) | Medical treatment period/drug(s) | |
|---|---|---|---|---|---|
26/10/12 | 50 × 25 | 27.4 | 90.1 | 22/11/2012–02/07/2013 | Tamoxifen 40 mg/day + arthrocine 200 mg/day |
18/03/13 | 50 × 25 | 27.1 | 89.1 | ||
18/06/13 | 54 × 26 | 30.4 | 100.0 | ||
28/11/13 | 51 × 18 | 24.7 | 81.3 | 02/07/2013–05/09/2013 | Sorafenib 400 mg/day |
27/06/14 | 50 × 22 | 26.5 | 87.2 | 05/09/2013–15/01/2015 | Sorafenib 200 mg/day |
12/12/14 | 49 × 21 | 25.6 | 84.2 | ||
21/04/15 | 49 × 23 | 26.4 | 86.9 | 15/01/2015–09/03/2015 | Interferon α2b 5 × 6 106 UI/week |
09/03/2015–20/05/2015 | Interferon α2b 5 × 6 106 UI/week + arthrocine 200 mg/day | ||||
14/01/16 | 32 × 21 | 15.3 | 50.3 | 30/05/2015–now | Sunitinib 25 mg/day by periods of 10 to 15 days |
01/07/16 | 31 × 18 | 13.2 | 43.4 | ||